RESUMO
Objective: The treatment timing of ureteropelvic junction obstruction (UPJO) in infants remains controversial. This study aimed to compare the recovery effect of renal morphology of immediate and delayed laparoscopic pyeloplasty in infants with severe UPJO. Methods: The infants with severe UPJO-induced hydronephrosis who underwent laparoscopic pyeloplasty according to their age at the time of surgery [the immediate treatment (IT) group: ≤1 month of birth, the delayed treatment (LT) group: 3-6 months of birth] in our center between 2010 and 2019 were enrolled in this study. Ultrasonography was used to assess renal morphology, including anteroposterior diameter (APD) of a pelvic, parenchymal thickness (PT), polar length (PL), and Society of Fetal Urology (SFU) grade. Preoperative and postoperative renal morphological outcomes at 6, 12, and 24 months were measured and compared. Results: During this period, a total of 135 patients were assigned to receive either IT (n = 73) or LT (n = 62) and were included for analysis. There were no significant differences in renal morphology indices at baseline between groups of IT and LT. The APD, PT, and PL in both groups all recovered to certain degrees compared with those at baseline, however, the IT group recovered more significantly than the LT group. Despite there being no significant difference in SFU grade between the two groups before and after surgery, the reduction of SFU grade in the IT group was more significant than that in the LT group during the 6-, 12- and 24-month follow-up periods. The PL, SFU, and APD were greater in the IT group than in the LT group at 6, 12, and 24 months of follow-up. At 6 months PL was not significantly higher between the two groups, while the outcome was significantly different at 12 months and 24 months. Conclusion: Immediate laparoscopic pyeloplasty for the infant with severe ureteropelvic junction obstruction is effective, and it can accelerate the recovery of renal morphological indices in infants with severe UPJO-induced hydronephrosis.
RESUMO
According to previous studies, linc-UBC1 is abnormally expressed in various human tumours. Nonetheless, the clinical significance and mechanism of linc-UBC1 in cancer remains unclear. In our present analysis, we wanted to explore the specific role of linc-UBC1 in malignant tumours by integrating all of the relevant literature and subsequently elucidating the relationship between linc-UBC1 expression level and clinical characteristics of cancers. An elaborate database search of PubMed, Embase, Wanfang Data, Web of Science, Ovid, Medline, Cochrane Library and PMC was carried out up to 8 August 2019. We further applied the pooled odds ratio (OR) and hazard ratio (HR) to evaluate OS. After filtering by strict criteria, 11 studies containing 1017 cases were included in this analysis. Our results implied that high expression of linc-UBC1 was obviously related to poor OS in cancer (HR =1.735, 95% 1.348-2.235, p < .001 random effects model). Analogously, the data revealed that high expression of linc-UBC1 was highly correlated with lymph node metastasis (OR = 2.912, 95% CI: 2.056-4.125, p < .001 fix effects model) and high tumour stage (OR = 2.678, 95% CI: 1.859-3.857, p < .001 fix effects model). In summary, linc-UBC1 overexpression is associated with poor OS and advanced tumour stage and could be used as a novel prognostic biomarker in various cancers.
